Ajinomoto Bio-Pharma Services vs Takeda: CDMO Comparison
How does Ajinomoto Bio-Pharma Services compare to Takeda for AAV manufacturing?
Side-by-side comparison of Ajinomoto Bio-Pharma Services and Takeda on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Takeda has more FDA inspections on record (4 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Takeda holds 18 active EMA GMP certificates; Ajinomoto Bio-Pharma Services does not appear in EudraGMDP.
- Ajinomoto Bio-Pharma Services maintains 1 MHRA / UK GMP certificate; Takeda does not.
- Takeda appears as a manufacturing partner on more matched clinical programs (100 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Ajinomoto Bio-Pharma Services and Takeda qualify as AAV manufacturers; Ajinomoto Bio-Pharma Services carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both Ajinomoto Bio-Pharma Services and Takeda qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: Ajinomoto Bio-Pharma Services vs Takeda
How does Ajinomoto Bio-Pharma Services compare to Takeda for AAV manufacturing?
On CDMO Signal's composite Signal Score, Ajinomoto Bio-Pharma Services is 84/100 and Takeda is 82/100; Ajinomoto Bio-Pharma Services has 0 FDA inspections on record vs 4 for Takeda; European coverage is 1 active EMA+MHRA certificate for Ajinomoto Bio-Pharma Services vs 18 for Takeda. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Ajinomoto Bio-Pharma Services or Takeda?
Both Ajinomoto Bio-Pharma Services and Takeda maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Ajinomoto Bio-Pharma Services has 0 FDA inspections on record; Takeda has 4.
How do Ajinomoto Bio-Pharma Services and Takeda compare on European GMP coverage?
Ajinomoto Bio-Pharma Services holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Takeda holds 18 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Ajinomoto Bio-Pharma Services or Takeda?
Ajinomoto Bio-Pharma Services is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Takeda is matched to 100. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for AAV manufacturing — Ajinomoto Bio-Pharma Services or Takeda?
Both Ajinomoto Bio-Pharma Services and Takeda are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →